SCHEMBL13879756

SCHEMBL13879756

COC(=O)c1cc(OC(=O)c2cc(NC(=O)c3cc(NC(=O)OC(C)(C)C)cn3C)cn2C)cn1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.38
LIPE Q05469 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PRKCA P17252 2/20 0.35
TOP1 P11387 2/20 0.35
HRAS P01112 1/20 0.35
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
KDM4E B2RXH2 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 1/20 0.34
HIF1A Q16665 1/20 0.34
LEF1 Q9UJU2 1/20 0.34
DRD2 P14416 1/20 0.34
ACHE P22303 1/20 0.34
BACE1 P56817 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
HPSE Q9Y251 1/20 0.33
NAMPT P43490 1/20 0.33
PRMT5 O14744 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13879751 0.92 P2RY12 (0.38) P2RY12LIPESMN1; SMN2TOP1HRAS
SCHEMBL4636432 0.92 P2RY12 (0.42) P2RY12PRKCATOP1HRASESR1
SCHEMBL3943496 0.92 P2RY12 (0.42) P2RY12PRKCATOP1HRASESR1
SCHEMBL2028885 0.92 P2RY12 (0.42) P2RY12PRKCATOP1HRASESR1
SCHEMBL3939869 0.92 P2RY12 (0.42) P2RY12PRKCATOP1HRASESR1
SCHEMBL3929339 0.92 P2RY12 (0.42) P2RY12PRKCATOP1HRASESR1
SCHEMBL13879725 0.87 HDAC1 (0.35) P2RY12LIPEPRKCATOP1HRAS
SCHEMBL2392134 0.87 HDAC3 (0.39) P2RY12KDM4ELEF1PRKDCHDAC3
SCHEMBL13879863 0.86 HDAC1 (0.37) P2RY12SMN1; SMN2LEF1HDAC1HDAC2
SCHEMBL13879867 0.85 HDAC3 (0.37) P2RY12LIPESMN1; SMN2POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8637664-B2 Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease SPIROGEN SARL (CH) 2014-01-28 US disclosed
US-8637664-B2 Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease SPIROGEN SARL (CH) 2014-01-28 US disclosed
EP-1931671-B1 ALKYL 4- [4- (5-OXO-2, 3, 5, 11A-TETRAHYD0-5H-PYRR0L0 [2, 1-C][1, 4]BENZODIAZEPINE-8-YLOXY) -BUTYRYLAMINO]-1H-PYRROLE-2-CARBOXYLATE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF A PROLIFERATIVE DISEASE SPIROGEN LTD (GB) 2009-04-08 EP disclosed
US-20080214525-A1 Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease SPIROGEN LIMITED (GB) 2008-09-04 US disclosed
US-20070154906-A1 Methods to identify therapeutic candidates SPIROGEN LTD. (GB) 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214525-A1 Alkyl 4- [4- (5-Oxo-2,3,5, 11A-Tetrahydo-5H-Pyrrolo [2, 1-C] [1,4] Benzodiazepine-8-Yloxy) -Butyrylamino]-1H-Pyrrole-2-Carboxylate Derivatives and Related Compounds For the Treatment of a Proliferative Disease CCNY, NR0B1, CNR1 P2RY12 3903/4885LIPE 4495/4885SMN1; SMN2 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.